Cara Therapeutics Crecimiento futuro
Future controles de criterios 2/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Cara Therapeutics de 16.7% y 34.7% por año respectivamente. Se prevé que el BPA crezca en un 28.7% al año. Se espera que la rentabilidad financiera sea de -103.4% en 3 años.
Información clave
16.7%
Tasa de crecimiento de los beneficios
28.7%
Tasa de crecimiento del BPA
Crecimiento de los beneficios de Pharmaceuticals | 22.8% |
Tasa de crecimiento de los ingresos | 34.7% |
Rentabilidad financiera futura | -103.4% |
Cobertura de analistas | Low |
Última actualización | 12 Apr 2024 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
We're A Little Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Feb 16The Market Doesn't Like What It Sees From Cara Therapeutics, Inc.'s (NASDAQ:CARA) Revenues Yet As Shares Tumble 43%
Dec 19News Flash: Analysts Just Made A Notable Upgrade To Their Cara Therapeutics, Inc. (NASDAQ:CARA) Forecasts
Nov 04Can Cara Therapeutics (NASDAQ:CARA) Afford To Invest In Growth?
Oct 25Is Cara Therapeutics (NASDAQ:CARA) In A Good Position To Deliver On Growth Plans?
Jul 20Take Care Before Jumping Onto Cara Therapeutics, Inc. (NASDAQ:CARA) Even Though It's 30% Cheaper
Jun 04News Flash: 8 Analysts Think Cara Therapeutics, Inc. (NASDAQ:CARA) Earnings Are Under Threat
Mar 11Cara Therapeutics, Inc. (NASDAQ:CARA) Analysts Just Slashed Next Year's Estimates
Feb 15We Think Cara Therapeutics (NASDAQ:CARA) Can Afford To Drive Business Growth
Feb 06We're Interested To See How Cara Therapeutics (NASDAQ:CARA) Uses Its Cash Hoard To Grow
Oct 18Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
Sep 28Cara Therapeutics hires new finance chief
Sep 12Cara Therapeutics: All Eyes On Korsuva Launch Metrics
Sep 01Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
Aug 19Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M
Aug 08Calls A Much Safer Way To Buy Cara Therapeutics
Jun 24We're Not Very Worried About Cara Therapeutics' (NASDAQ:CARA) Cash Burn Rate
Jun 15Brokers Are Upgrading Their Views On Cara Therapeutics, Inc. (NASDAQ:CARA) With These New Forecasts
May 12Taking A (Speculative) Position In Cara Therapeutics
Mar 21Companies Like Cara Therapeutics (NASDAQ:CARA) Are In A Position To Invest In Growth
Mar 09Cara Therapeutics: De-Risked And Extremely Attractive
Dec 25Checking Back In On Cara Therapeutics
Nov 01Cara And IV Korsuva: Key Bull And Bear Investor Thoughts Going Into Upcoming PDUFA
Aug 21The Consensus EPS Estimates For Cara Therapeutics, Inc. (NASDAQ:CARA) Just Fell Dramatically
Aug 15Cara Therapeutics: 200% Upside Possible With FDA Approval
Aug 11Cara Therapeutics: PDUFA Ahead Makes Current Drop Attractive
Jul 19It's Unlikely That The CEO Of Cara Therapeutics, Inc. (NASDAQ:CARA) Will See A Huge Pay Rise This Year
May 28Previsiones de crecimiento de beneficios e ingresos
Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
---|---|---|---|---|---|
12/31/2026 | 4 | -62 | -23 | -30 | 5 |
12/31/2025 | 4 | -67 | -39 | -46 | 5 |
12/31/2024 | 6 | -64 | -55 | -48 | 5 |
12/31/2023 | 21 | -119 | -94 | -92 | N/A |
9/30/2023 | 21 | -117 | -99 | -98 | N/A |
6/30/2023 | 27 | -112 | -104 | -104 | N/A |
3/31/2023 | 43 | -84 | -88 | -88 | N/A |
12/31/2022 | 42 | -85 | -79 | -79 | N/A |
9/30/2022 | 39 | -89 | -57 | -56 | N/A |
6/30/2022 | 49 | -66 | -45 | -45 | N/A |
3/31/2022 | 26 | -93 | -62 | -62 | N/A |
12/31/2021 | 23 | -88 | -60 | -60 | N/A |
9/30/2021 | 134 | 24 | 23 | 23 | N/A |
6/30/2021 | 123 | 8 | 15 | 16 | N/A |
3/31/2021 | 129 | 14 | 9 | 9 | N/A |
12/31/2020 | 135 | 8 | -6 | -5 | N/A |
9/30/2020 | 28 | -99 | -119 | -119 | N/A |
6/30/2020 | 24 | -115 | -123 | -123 | N/A |
3/31/2020 | 24 | -113 | -120 | -120 | N/A |
12/31/2019 | 20 | -106 | -109 | -109 | N/A |
9/30/2019 | 21 | -98 | -102 | -102 | N/A |
6/30/2019 | 20 | -85 | -97 | -97 | N/A |
3/31/2019 | 18 | -79 | -31 | -31 | N/A |
12/31/2018 | 13 | -74 | -22 | -22 | N/A |
9/30/2018 | 8 | -68 | -9 | -9 | N/A |
6/30/2018 | 3 | -61 | 1 | 1 | N/A |
3/31/2018 | N/A | -53 | -52 | -52 | N/A |
12/31/2017 | 1 | -58 | -55 | -55 | N/A |
9/30/2017 | 1 | -66 | N/A | -57 | N/A |
6/30/2017 | 1 | -65 | N/A | -60 | N/A |
3/31/2017 | 1 | -69 | N/A | -59 | N/A |
12/31/2016 | 0 | -57 | N/A | -47 | N/A |
9/30/2016 | 0 | -45 | N/A | -38 | N/A |
6/30/2016 | 3 | -38 | N/A | -33 | N/A |
3/31/2016 | 3 | -31 | N/A | -26 | N/A |
12/31/2015 | 4 | -25 | N/A | -21 | N/A |
9/30/2015 | 5 | -19 | N/A | -23 | N/A |
6/30/2015 | 3 | -21 | N/A | -20 | N/A |
3/31/2015 | 3 | -19 | N/A | -20 | N/A |
12/31/2014 | 3 | -18 | N/A | -18 | N/A |
9/30/2014 | 3 | -16 | N/A | -17 | N/A |
6/30/2014 | 3 | -14 | N/A | -16 | N/A |
3/31/2014 | 12 | -6 | N/A | 2 | N/A |
12/31/2013 | 12 | -3 | N/A | 3 | N/A |
9/30/2013 | 11 | -3 | N/A | 6 | N/A |
6/30/2013 | 11 | 1 | N/A | 9 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CARA siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que CARA siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que CARA siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (34.7% al año) de CARA crezcan más rápidamente que los del mercado US (7.9% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos (34.7% al año) de CARA crezcan más rápidamente que un 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: CARA se prevé que no sea rentable en 3 años.